ARNAV Biotech Secures Exclusive License for Cutting-edge Anti-RSV Inhibitor from Alabama State University
Atlanta, Georgia and Montgomery, Alabama, 1 January 2024
We are thrilled to announce exclusive license agreement with Alabama State University for a novel anti-respiratory syncytial virus (RSV) therapeutics. RSV causes bronchiolitis and severe lower respiratory tract infections in infants leading to nearly 50,000–80,000 hospitalization among U.S. infants and children under the age of 5; most children are infected during the first year of life, and nearly all have been infected by age 2 years. It can also cause severe infections in elderly and immunocompromised. Unfortunately, there is no approved treatment for infants and children, or elderly.
ARNV-F2 (tentatively named), is a fusion inhibitor that blocks the fusion of RSV to host cells, thus, halting infection.
With this agreement ARNAV will be uniquely positioned to move this drug quickly to the pre-IND and IND enabling studies. Dr. Shree Ram Singh, inventor of this drug, at Alabama State University and Co-founder and CEO or ARNAV Biotech said in a statement, “This licensing agreement is a significant milestone in ARNAV’s business model which enables us to take the anti-RSV innovation to the marketplace. With our strong technological capabilities, we are able to bring the product to treat RSV disease which has become a significant health issue since the COVID pandemic”.
Dr. Pooja M. Tiwari, co-inventor of this drug and COO at ARNAV Biotech said, “I am thrilled to see what we develop as my Ph. D. project move one step closer from bench to the bedside. As a mother of a young child, I always worried whether the virus I studied for so long, affect my child or anyone else. Luckily, we were saved from RSV, but there are thousands of infants and young children and even elderly, suffering from RSV related complications. This brings hope to parents and caregivers like me to have something to treat severe RSV infections, hopefully very soon. We are looking for partners to advance the clinical development of this drug”.
For investment or collaboration opportunities please email: info@arnavbiotech.com
For more information visit: www.arnavbiotech.com
About Alabama State University: Alabama State Universitys is a public historically black university (HBCU) in Montgomery, Alabama. Founded in 1867, during the Reconstruction era, it was one of about 180 “normal schools” established by state governments in the 19th century to train teachers for the rapidly growing public common schools. Some of the 180 closed but most steadily expanded their role and became state colleges in the early 20th century and state universities in the late 20th century. ASU is a member-school of the Thurgood Marshall College Fund.
About Arnav Biotech: ARNAV Biotech is an Atlanta, US based mRNA therapeutics and CDRMO developing anti-viral therapeutics, mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities as well lipid and other nanoparticle delivery vehicles. For more information, please contact us at info@arnavbiotech.com or visit www.arnavbiotech.com.
Sartorius BIA Separations and Arnav Biotech enter in collaboration to develop a mRNA synthesis and purification platform, supported with PATfix in-process analytical solution
Atlanta, Georgia and Ajdovscina, Slovenia, 2 February 2023
- Project combines Sartorius BIA Separations’ platforms for purification and analytics with Arnav’s innovative mRNA pipeline.
- The collaboration will leverage the companies’ track records in mRNA design, cost-efficient production and purification process and biological testing capabilities to develop a unique mRNA platform with low CoGs and high product purity
Sartorius BIA Separations (BIA), which is part of the international life science group Sartorius, and Arnav Biotech, an mRNA therapeutics and CDRMO developing mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities, are entering into a collaboration to develop a purification and analytical platform for the Arnav Biotech mRNA pipeline.
The new development will be based on the BIA chromatographic platform. Its PATfix™ analytical system will be used to optimize mRNA synthesis, purification, and quality control of Arnav’s therapeutics modalities. Together, Arnav Biotech and BIA plan to develop robust mRNA synthesis and purification processes to progress Arnav’s therapeutic pipeline to advanced clinical stages.
The objective of the project is to achieve the highest quality mRNA synthesis and purification process that is economic and adaptable across various therapeutic and vaccine platforms. This would enable Arnav to attain the highest mRNA yields with minimal non-ssRNA, DNA and other contaminants. This collaboration will promote an innovative approach with Cornerstone process development algorithm that will be applied to multiple mRNA designs.
The project will begin in April and reach development milestone by September 2023.
About Sartorius BIA Separations:
Sartorius BIA Separations is the leading developer of monolith technology and the exclusive producer of CIM® (Convective Interaction Media) chromatographic columns for the production, purification, and analysis of large biomolecules. The Company’s multi-use research, production, and training facility is headquartered in Ajdovščina, Slovenia, with sales and distribution offices located internationally.
Sartorius BIA Separations’ ongoing mission is to develop and produce CIM® monolithic columns of the highest quality and provide superior research and method development services for our customers. In addition, the Company now offers the highly versatile PATfix™ analytical system which enables analytical gradient separations.
Arnav Biotech is an US based mRNA therapeutics and CDRMO developing mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities. Arnav is advancing its mRNA platform and process development to enhance the targeted expression of its diverse therapeutic candidates while unifying the synthesis and purification process. For more information, please contact us at info@arnavbiotech.com or visit www.arnavbiotech.com.